Engineered immune cells take aim at Hard-to-Treat T-Cell cancers

NCT ID NCT07678307

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study tests a new treatment called nano CD5-CAR T cells for people with relapsed or refractory T-cell acute lymphoblastic leukemia or T-cell lymphoma. The therapy uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells that carry the CD5 protein. The trial has two phases: the first checks safety and the best dose, and the second looks at how well the treatment works. Participants receive chemotherapy before a single infusion of the modified cells.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
autologous nano CD5-CAR T cells
What this could lead to
If it works, this could offer a new treatment option for people with hard-to-treat T-cell cancers that have not responded to standard therapy.
What could go wrong
This is an early-phase trial with only 18 participants, so results may not apply broadly. Risks include fever, low blood pressure, and infection, and the therapy may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY HEMATOLOGIC MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.